ºÒ¸éÁõ Ä¡·á ½ÃÀå : Ä¡·áÁ¦ À¯Çüº°, ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, ±¹°¡º°, Áö¿ªº° - ¼¼°è »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× ¿¹Ãø(2025-2032³â)
Insomnia Therapeutics Market, By Therapeutics Type, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1684286
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ºÒ¸éÁõ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2024³â 29¾ï 232¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 4.90%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

ºÒ¸éÁõ Ä¡·á ½ÃÀå - ½ÃÀå ¿ªÇÐ

Á¤½ÅÁúȯ Áõ°¡·Î ºÒ¸éÁõ Ä¡·á ¼ö¿ä Áõ°¡ °ßÀÎ

ºÒ¾È, ¿ì¿ïÁõ, ½ºÆ®·¹½º °ü·Ã Àå¾Ö¿Í °°Àº ÁúȯÀÌ ¼ö¸éÀå¾ÖÀÇ ¿øÀÎÀÌ µÉ ¼ö Àֱ⠶§¹®¿¡ Á¤½Å °Ç°­ Áúȯ Áõ°¡´Â ºÒ¸éÁõ Ä¡·á ¼ö¿ä¸¦ Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¿ì¿ïÁõÀº Àü ¼¼°èÀûÀ¸·Î 2¾ï 8,000¸¸ ¸í ÀÌ»óÀÌ ¾Î°í ÀÖÀ¸¸ç, ¼ö¸éÀå¾Ö´Â ÈçÇÑ Áõ»óÀÔ´Ï´Ù. ¹Ì±¹ ±¹¸³Á¤½Å°Ç°­¿¬±¸¼Ò(NIMH)´Â ºÒ¾ÈÀå¾Ö°¡ ÀÖ´Â »ç¶÷Àº ¸¸¼º ºÒ¸éÁõ¿¡ °É¸± À§ÇèÀÌ ³ô´Ù°í °­Á¶ÇÕ´Ï´Ù. ÀÌ¿¡ µû¶ó ºÒ¸éÁõ¿¡ ´ëÇÑ ÀÎÁöÇൿġ·á(CBT-I)°¡ 1Â÷ ¼±Åà ġ·á·Î äÅõǰí ÀÖÀ¸¸ç, ±âÁ¸ ÁøÁ¤Á¦¿¡ ºñÇØ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀÌ °³¼±µÈ ÀÌÁß ¿Ã·¹½Å ¼ö¿ëü ±æÇ×Á¦¿Í °°Àº ¾à¸®ÇÐÀû ÇØ°áÃ¥µµ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, FDA ½ÂÀÎÀ» ¹ÞÀº Somryst¿Í °°Àº µðÁöÅÐ Ä¡·áÁ¦´Â Á¤½Å °Ç°­ °ü¸® °èȹ¿¡ ÅëÇÕµÇ¾î ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ºñ¾à¹°Àû Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Á¤½Å°Ç°­°ú ¼ö¸éÀå¾ÖÀÇ ¿¬°ü¼ºÀÌ Àνĵʿ¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í Á¦¾àȸ»çµéÀº º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ ºÒ¸éÁõ Ä¡·á¸¦ °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

ºÒ¸éÁõ Ä¡·á ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 4.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Ä¡·áÁ¦ À¯Çüº° ¼¼ºÐÈ­¿¡ µû¸£¸é, 2024³â¿¡´Â ºñº¥Á¶µð¾ÆÁ¦ÇÉ °è¿­ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¾àÈ¿±ºº°·Î´Â 2024³â ºñº¥Á¶µð¾ÆÁ¦Çɰè ÃÖ¸éÁ¦°¡ ÁÖ¿ä ¾àÈ¿±ºÀÌ µÇ¾ú½À´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â °æ±¸Á¦°¡ 2024³â ÁÖ¿ä Åõ¿© °æ·Î°¡ µÇ¾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâ 1À§¸¦ ±â·ÏÇß½À´Ï´Ù.

ºÒ¸éÁõ Ä¡·á ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ºÒ¸éÁõ Ä¡·á ½ÃÀåÀº Ä¡·áÁ¦ À¯Çü, ¾à¹° À¯Çü, ¾à¹° Ŭ·¡½º, Åõ¿© °æ·Î, À¯Åë ä³Î, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Ä¡·áÁ¦ À¯Çü¿¡ µû¶ó º¥Á¶µð¾ÆÁ¦Çɰè, ºñº¥Á¶µð¾ÆÁ¦Çɰè, Ç׿ì¿ïÁ¦, ¿Ã·º½Å ±æÇ×Á¦, ¸á¶óÅä´Ñ ±æÇ×Á¦, ±âŸ 5°¡Áö Ä«Å×°í¸®·Î ºÐ·ùµË´Ï´Ù. ºñº¥Á¶µð¾ÆÁ¦Çɰè Ç׿ì¿ïÁ¦´Â È¿°ú¿Í ³·Àº ÀÇÁ¸¼º À§ÇèÀ¸·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ±× µÚ¸¦ ÀÌ¾î ¿Ã·¹½Å ±æÇ×Á¦°¡ º¸´Ù ¾ÈÀüÇÑ ´ë¾ÈÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. Ç׿ì¿ïÁ¦´Â ºÒ¸éÁõ°ú ÇÔ²² ºÒ¸éÁõ¿¡ ³Î¸® ó¹æµÇ°í ÀÖÁö¸¸, º¥Á¶µð¾ÆÁ¦ÇÉ °è¿­Àº ÀÇÁ¸¼º ¿ì·Á¿¡µµ ºÒ±¸ÇÏ°í ¿©ÀüÈ÷ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸á¶óÅä´Ñ ±æÇ×Á¦ ¹× ±âŸ Ä¡·áÁ¦´Â ƯÁ¤ ȯÀÚµéÀÇ ¿ä±¸¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¾à¹° À¯Çüº°·Î º¥Á¶µð¾ÆÁ¦Çɰè ÃÖ¸éÁ¦, ºñº¥Á¶µð¾ÆÁ¦Çɰè ÃÖ¸éÁ¦, ¸á¶óÅä´Ñ ¼ö¿ëü ÀÛ¿ëÁ¦, ¿Ã·¹½Å ¼ö¿ëü ±æÇ×Á¦, Ç׿ì¿ïÁ¦ µî 6°¡Áö Ä«Å×°í¸®·Î ºÐ·ùµË´Ï´Ù. ºñº¥Á¶µð¾ÆÁ¦Çɰè ÃÖ¸éÁ¦´Â È¿°ú¿Í ÀÇÁ¸¼º À§Çè °¨¼Ò·Î ÀÎÇØ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ¿Ã·¹½Å ¼ö¿ëü ±æÇ×Á¦´Â º¸´Ù ¾ÈÀüÇÑ ´ë¾ÈÀ¸·Î ºü¸£°Ô ½ÃÀå Á¡À¯À²À» ´Ã·Á°¡°í ÀÖ½À´Ï´Ù. Ç׿ì¿ïÁ¦´Â Á¤½ÅÁúȯ°ú °ü·ÃµÈ ºÒ¸éÁõ¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, º¥Á¶µð¾ÆÁ¦Çɰè ÃÖ¸éÁ¦¿Í ¸á¶óÅä´Ñ ¼ö¿ëü ÀÛ¿ëÁ¦´Â Æ´»õ ȯÀÚÃþ¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

ºÒ¸éÁõ Ä¡·á ½ÃÀå - Áö¸®Àû ÅëÂû·Â

ºÒ¸éÁõÀÇ ³ôÀº À¯º´·ü, Á¤½ÅÁúȯ Áõ°¡, °­·ÂÇÑ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ ºÏ¹Ì´Â ºÒ¸éÁõ Ä¡·á ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹¿¡¼­´Â ºÒ¸éÁõ¿¡ ´ëÇÑ ÀÎÁöÇൿġ·á(CBT-I)¿Í 󹿾àÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, FDA´Â Darydrexant¿Í °°Àº »õ·Î¿î ¼¼´ëÀÇ ¼ö¸é º¸Á¶Á¦¸¦ ½ÂÀÎÇß½À´Ï´Ù. À¯·´¿¡¼­µµ ¼ö¸éÀå¾Ö¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Á¤ºÎ Áö¿ø Á¤½Å °Ç°­ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÈûÀÔ¾î ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µî¿¡¼­´Â AI¸¦ Ȱ¿ëÇÑ ¼ö¸é ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀ» ÅëÇÕÇÑ µðÁöÅÐ Ä¡·áÁ¦°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, ¾÷¹« °ü·Ã ½ºÆ®·¹½º, µµ½ÃÈ­°¡ ºÒ¸éÁõ, ƯÈ÷ Áß±¹, ÀϺ», Àεµ¿¡¼­ ºÒ¸éÁõ ¹ßº´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡¿¡¼­´Â Çãºê ¹× ´ëü ¼ö¸é Ä¡·áÁ¦ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ µ¶Æ¯ÇÑ ½ÃÀå µ¿ÇâÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ½ÅÈï ½ÃÀåÀ¸·Î, ÀÇ·á Á¢±Ù¼º Çâ»ó°ú ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÌ ÀǾàǰ ¹× ºñÀǾàǰ ºÒ¸éÁõ Ä¡·áÀÇ Á¡ÁøÀûÀΠäÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÒ¸éÁõ Ä¡·á ½ÃÀå - °æÀï ±¸µµ:

ºÒ¸éÁõ Ä¡·á ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ´ëÇü Á¦¾à»ç, µðÁöÅÐ Çコ ±â¾÷, ½Å»ý ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷µéÀº Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÇÁ·ÎÆÄÀÏÀÌ °³¼±µÈ ¼öº¸·º»êÆ®, ´Þ¸®µå·º»êÆ® µî ÀÌÁß ¿Ã·¹½Å ¼ö¿ëü ±æÇ×Á¦ µî Â÷¼¼´ë ºÒ¸éÁõ Ä¡·á¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÀçÁî ÆÄ¸¶½´Æ¼Äýº(Jazz Pharmaceuticals)³ª È­ÀÌÀÚ¿Í °°Àº ±â¾÷µéÀº ¼ö¸éÀå¾Ö Ä¡·áÁ¦ Æ÷Æ®Æú¸®¿À¸¦ Áö¼ÓÀûÀ¸·Î È®ÀåÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Å×¶óǻƽ½º ºÐ¾ßµµ ¼ºÀåÇϰí ÀÖÀ¸¸ç, ÇǾîÅ×¶óǻƽ½ºÀÇ Somryst¿Í °°Àº FDA ½ÂÀÎ ¼Ö·ç¼ÇÀº ºÒ¸éÁõ¿¡ ´ëÇÑ ÀÎÁöÇൿġ·á(CBT-I)¸¦ ÅëÇÑ ºñ¾à¹°Àû ´ëü¿ä¹ýÀ» Á¦°øÇÕ´Ï´Ù. ½ºÅ¸Æ®¾÷°ú ÇÏÀÌÅ×Å© ±â¾÷µéÀº AI¸¦ Ȱ¿ëÇÑ ¼ö¸é ¸ð´ÏÅ͸µ ±â±â ¹× ¿þ¾î·¯ºí ±â¼úÀ» °³¹ßÇÏ¿© Ä¡·á Á¢±Ù¹ýÀ» °³ÀÎÈ­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¹ßÀü¿¡µµ ºÒ±¸Çϰí, ¾à¹° ÀÇÁ¸¼º ¿ì·Á, ±ÔÁ¦ À庮, ÇѾà°ú °°Àº ´ëü Ä¡·á¹ý°úÀÇ °æÀï µîÀÇ ¹®Á¦°¡ ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. Àü·«Àû Á¦ÈÞ, Á¦Ç° Çõ½Å, À¯Åë¸Á È®´ë´Â ºÒ¸éÁõ Ä¡·á ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷µé¿¡°Ô ¿©ÀüÈ÷ Áß¿äÇÑ Àü·«ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÒ¸éÁõ Ä¡·á ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ºÒ¸éÁõ Ä¡·á »ê¾÷ Á¶»ç

Á¦5Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå ±¸µµ

Á¦7Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå - Ä¡·áÁ¦ À¯Çüº°

Á¦8Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå - ¾àÁ¦ Ŭ·¡½ºº°

Á¦9Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå - Åõ¿© °æ·Îº°

Á¦10Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå - À¯Åë ä³Îº°

Á¦11Àå ºÒ¸éÁõ Ä¡·á ½ÃÀå - Áö¿ª

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ºÒ¸éÁõ Ä¡·á ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ ´Ù°¢Àû °ßÇØ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Insomnia Therapeutics Market size was valued at US$ 2,902.32 Million in 2024, expanding at a CAGR of 4.90% from 2025 to 2032.

The insomnia therapeutics market focuses on treatments designed to manage and alleviate sleep disorders, particularly chronic and acute insomnia. Rising stress levels, increasing cases of mental health disorders, and lifestyle changes have significantly contributed to the growing prevalence of insomnia, with the CDC reporting that one in three adults in the U.S. does not get enough sleep. Pharmaceutical advancements, including orexin receptor antagonists like lemborexant and daridorexant, are enhancing treatment efficacy while reducing dependency risks associated with traditional benzodiazepines. Additionally, the expansion of cognitive behavioral therapy for insomnia (CBT-I) as a preferred non-pharmacological intervention is gaining traction, with digital therapeutics platforms like Somryst receiving FDA approval. However, side effects related to sedative-hypnotic drugs and the risk of dependency pose challenges to market growth. Opportunities lie in integrating AI-powered sleep monitoring devices and wearable technology, which provide personalized therapy insights. As awareness of sleep health increases, the demand for innovative and safer insomnia treatments continues to grow.

Insomnia Therapeutics Market- Market Dynamics

Rising Mental Health Disorders Driving Demand for Insomnia Therapeutics

Rising mental health disorders are significantly driving demand for insomnia therapeutics, as conditions like anxiety, depression, and stress-related disorders contribute to sleep disturbances. According to the World Health Organization (WHO), depression affects over 280 million people worldwide, with sleep issues being a common symptom. The National Institute of Mental Health (NIMH) highlights that individuals with anxiety disorders are at a higher risk of developing chronic insomnia. This has led to increased adoption of cognitive behavioral therapy for insomnia (CBT-I) as a first-line treatment, alongside advancements in pharmacological solutions such as dual orexin receptor antagonists, which offer improved safety profiles compared to traditional sedatives. Additionally, digital therapeutics like FDA-approved Somryst are being integrated into mental health care plans, providing accessible, non-drug treatment options. The growing recognition of the link between mental health and sleep disorders is pushing healthcare providers and pharmaceutical companies to develop more effective and personalized insomnia therapies.

Insomnia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2025-2032)

Based on Therapeutics Type segmentation, Nonbenzodiazepines was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, non-benzodiazepine hypnotics was the leading Drug Class in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Insomnia Therapeutics Market- Segmentation Analysis:

The Global Insomnia Therapeutics Market is segmented on the basis of Therapeutics Type, Drug Class, Route of Administration, Distribution Channel, and Region.

The market is divided into five categories based on Therapeutics Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, and Others. Nonbenzodiazepines lead the market due to their effectiveness and lower dependency risk. Orexin antagonists follow, gaining traction as safer alternatives. Antidepressants are widely prescribed for comorbid insomnia, while benzodiazepines remain in use despite dependency concerns. Melatonin antagonists and other therapies cater to specific patient needs.

The market is divided into six categories based on Drug Class: Benzodiazepines, Non-Benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, and Antidepressants. Non-benzodiazepine hypnotics dominate due to their efficacy and reduced dependency risks. Orexin receptor antagonists are rapidly gaining market share as safer alternatives. Antidepressants are widely used for insomnia linked to mental health conditions, while benzodiazepines and melatonin receptor agonists serve niche patient segments.

Insomnia Therapeutics Market- Geographical Insights

North America dominates the insomnia therapeutics market due to high insomnia prevalence, rising mental health disorders, and strong healthcare infrastructure. The U.S., in particular, sees widespread adoption of cognitive behavioral therapy for insomnia (CBT-I) and prescription medications, with the FDA approving new-generation sleep aids like daridorexant. Europe follows closely, with increasing awareness of sleep disorders and government-backed mental health initiatives driving demand for advanced therapeutics. Countries such as Germany, the UK, and France are witnessing a surge in digital therapeutics, integrating AI-powered sleep monitoring solutions. In the Asia-Pacific region, changing lifestyles, work-related stress, and urbanization contribute to a growing insomnia burden, particularly in China, Japan, and India. The rising use of herbal and alternative sleep remedies in these countries also presents a unique market trend. Meanwhile, Latin America and the Middle East & Africa are emerging markets, where increasing healthcare access and awareness campaigns are driving gradual adoption of pharmaceutical and non-pharmaceutical insomnia treatments.

Insomnia Therapeutics Market- Competitive Landscape:

The insomnia therapeutics market is highly competitive, with pharmaceutical giants, digital health companies, and emerging biotech firms focusing on innovative treatment solutions. Leading players such as Merck & Co., Eisai Co., and Idorsia Pharmaceuticals are advancing next-generation insomnia drugs, including dual orexin receptor antagonists like suvorexant and daridorexant, which offer improved safety profiles over traditional sedatives. Meanwhile, companies like Jazz Pharmaceuticals and Pfizer continue to expand their sleep disorder drug portfolios. The digital therapeutics segment is also gaining traction, with FDA-approved solutions such as Pear Therapeutics' Somryst offering non-drug alternatives through cognitive behavioral therapy for insomnia (CBT-I). Startups and tech firms are developing AI-driven sleep monitoring devices and wearable technology to personalize treatment approaches. Despite market advancements, challenges such as drug dependency concerns, regulatory hurdles, and competition from alternative treatments like herbal remedies impact market dynamics. Strategic collaborations, product innovation, and expanding distribution networks remain key strategies for companies aiming to strengthen their market presence in insomnia therapeutics.

Recent Developments:

In July 2020, Eisai launched DAYVIGO(R) (lemborexant) in Japan, for treating insomnia. This dual orexin receptor antagonist facilitates sleep onset and maintenance. Approval was based on Phase III trials showing improved sleep compared to placebo and zolpidem, with somnolence, headache, and dizziness as main side effects.

In December 2024, Shionogi and Nxera Pharma launched QUVIVIQ(TM) (daridorexant) in Japan as a new treatment for adults with insomnia. This oral medication selectively blocks orexin receptors, promoting sleep by inhibiting excessive wakefulness. Shionogi will handle distribution and sales.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INSOMNIA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY THERAPEUTICS TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Insomnia Therapeutics Market Overview

2. Executive Summary

3. Insomnia Therapeutics Key Market Trends

4. Insomnia Therapeutics Industry Study

5. Insomnia Therapeutics Market: Impact of Escalating Geopolitical Tensions

6. Insomnia Therapeutics Market Landscape

7. Insomnia Therapeutics Market - By Therapeutics Type

8. Insomnia Therapeutics Market - By Drug Class

9. Insomnia Therapeutics Market - By Route of Administration

10. Insomnia Therapeutics Market - By Distribution Channel

11. Insomnia Therapeutics Market- By Geography

12. Key Vendor Analysis- Insomnia Therapeutics Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â